RT Journal Article
SR Electronic
T1 Effectiveness of bivalent mRNA booster vaccination against SARS-CoV-2 Omicron infection in the Netherlands, September to December 2022
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.02.08.23285643
DO 10.1101/2023.02.08.23285643
A1 Anne J. Huiberts
A1 Brechje de Gier
A1 Christina E. Hoeve
A1 Hester E. de Melker
A1 Susan J.M. Hahné
A1 Gerco den Hartog
A1 Janneke H.H.M. van de Wijgert
A1 Susan van den Hof
A1 Mirjam J. Knol
YR 2023
UL http://medrxiv.org/content/early/2023/02/13/2023.02.08.23285643.abstract
AB We used data of 32,542 prospective cohort study participants who previously received primary and one or two monovalent booster COVID-19 vaccinations. Between 26 September and 19 December 2022, relative effectiveness of bivalent Original/Omicron BA.1 vaccination against self-reported Omicron SARS-CoV-2 infection was 31% in 18-59-year-olds and 14% in 60-85-year-olds. Protection was higher after prior Omicron infection than after bivalent vaccination without prior infection. Although bivalent booster vaccination increases protection against COVID-19 hospitalizations, we found limited added benefit in preventing SARS-CoV-2 infection.Competing Interest StatementThe authors have declared no competing interest.Clinical Protocols https://trialsearch.who.int/Trial2.aspx?TrialID=NL9279 https://www.researchgate.net/publication/360721847_Design_and_baseline_description_of_an_observational_population-based_cohort_study_on_COVID-19_vaccine_effectiveness_in_the_Netherlands_-_The_VAccine_Study_COvid-19_VASCO Funding StatementThis study was funded by the Dutch Ministry of Health, Welfare and SportAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Medical Ethics Committee of the Stichting Beoordeling Ethiek Biomedisch Onderzoek, Assen, the Netherlands, gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available in aggregated and anonymized form upon reasonable request to the authors.